These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26407364)

  • 21. Rapid online identification of adverse events after influenza immunization in children by PCIRN's National Ambulatory Network.
    Bettinger JA; Vanderkooi OG; MacDonald J; Kellner JD
    Pediatr Infect Dis J; 2014 Oct; 33(10):1060-4. PubMed ID: 25361187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
    Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA
    Vaccine; 2015 Jun; 33(29):3415-21. PubMed ID: 25917680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children.
    Asturias EJ; Contreras-Roldan IL; Ram M; Garcia-Melgar AJ; Morales-Oquendo V; Hartman K; Rauscher M; Moulton LH; Halsey NA
    Vaccine; 2013 Dec; 31(49):5909-14. PubMed ID: 24055354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy.
    Regan AK; Tracey LE; Blyth CC; Richmond PC; Effler PV
    Vaccine; 2016 Apr; 34(20):2299-304. PubMed ID: 27038132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children.
    Cashman P; Moberley S; Dalton C; Stephenson J; Elvidge E; Butler M; Durrheim DN
    Vaccine; 2014 Sep; 32(42):5503-8. PubMed ID: 25077424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.
    Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G
    Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States.
    Broder KR; Martin DB; Vellozzi C
    Vaccine; 2012 Mar; 30(11):2032-4. PubMed ID: 22361305
    [No Abstract]   [Full Text] [Related]  

  • 28. Near real-time vaccine safety surveillance with partially accrued data.
    Greene SK; Kulldorff M; Yin R; Yih WK; Lieu TA; Weintraub ES; Lee GM
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):583-90. PubMed ID: 21538670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].
    Alguacil Ramos AM; Lluch Rodrigo JA; Portero Alonso A; Martín Ivorra R; Pastor Villalba E
    Rev Esp Salud Publica; 2012; 86(3):241-51. PubMed ID: 22991081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outliers and patients with adverse drug reactions.
    Edwards IR
    Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS).
    Wei L; Scott J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):922-33. PubMed ID: 26045284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
    Li AS; Pomeranz HD
    J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
    [No Abstract]   [Full Text] [Related]  

  • 34. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.
    Li R; Stewart B; McNeil MM; Duffy J; Nelson J; Kawai AT; Baxter R; Belongia EA; Weintraub E
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):928-34. PubMed ID: 27037540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P; Toback SL; Andrews EB; McQuay LJ; Ambrose CS
    Vaccine; 2012 Sep; 30(42):6099-102. PubMed ID: 22841479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Field study of physicians on the incidence of adverse vaccine effects and vaccine reactions in early summer meningoencephalitis, tetanus and influenza vaccination in general practice].
    Schmeiser-Rieder A; Kunze M
    Wien Med Wochenschr; 1998; 148(8-9):214-5. PubMed ID: 9677685
    [No Abstract]   [Full Text] [Related]  

  • 38. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(19):2989-98. PubMed ID: 22386746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine safety signal from spontaneous system not supported by active surveillance.
    Thompson CA
    Am J Health Syst Pharm; 2014 Sep; 71(17):1432-3. PubMed ID: 25147163
    [No Abstract]   [Full Text] [Related]  

  • 40. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.
    Parretta E; Ianniello B; Ferrazin F; Rossi F; Capuano A
    Vaccine; 2011 May; 29(20):3708-13. PubMed ID: 21406267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.